MCID: PRS021
MIFTS: 52

Prostatic Adenoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Prostatic Adenoma

MalaCards integrated aliases for Prostatic Adenoma:

Name: Prostatic Adenoma 12 55 15 72
Prostatic Hyperplasia 44 72
Benign Prostatic Hyperplasia 72
Benign Adenoma of Prostate 12
Adenoma of Prostate 12
Adenoma - Prostate 12
Prostate Adenoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2883
MeSH 44 D011470
NCIt 50 C4795
SNOMED-CT 68 21173002
UMLS 72 C0520477 C1704272 C2937421

Summaries for Prostatic Adenoma

Disease Ontology : 12 A male reproductive organ benign neoplasm that derives from glandular epithelial cells and that is located in the prostate.

MalaCards based summary : Prostatic Adenoma, also known as prostatic hyperplasia, is related to prostatic hypertrophy and prostatic hyperplasia, benign, and has symptoms including prostatism An important gene associated with Prostatic Adenoma is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Scopolamine and Saw palmetto have been mentioned in the context of this disorder. Affiliated tissues include prostate, testes and smooth muscle, and related phenotypes are Decreased substrate adherent cell growth and cardiovascular system

Related Diseases for Prostatic Adenoma

Diseases related to Prostatic Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 293)
# Related Disease Score Top Affiliating Genes
1 prostatic hypertrophy 31.0 KLK3 ADRA1A
2 prostatic hyperplasia, benign 31.0 KLK3 ADRA1A
3 prostatitis 30.6 KLK3 ADRA1A
4 hypertension, essential 28.6 ADRB1 ADRA2B ADRA1D
5 benign prostate phyllodes tumor 11.3
6 adenoma 11.2
7 impotence 11.0
8 sexual disorder 10.7
9 pure autonomic failure 10.5
10 overgrowth syndrome 10.5
11 adenocarcinoma 10.4
12 body mass index quantitative trait locus 1 10.4
13 pulmonary alveolar microlithiasis 10.4
14 suppression of tumorigenicity 12 10.4
15 pachyonychia congenita 3 10.3
16 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.3
17 aging 10.3
18 neurogenic bladder 10.3
19 alopecia 10.3
20 insulin-like growth factor i 10.3
21 hyperinsulinism 10.3
22 infant gynecomastia 10.3
23 gynecomastia 10.3
24 48,xyyy 10.3
25 androgenic alopecia 10.2
26 b-cell lymphoma 10.2
27 pyelonephritis 10.2
28 mycobacterium tuberculosis 1 10.2
29 cystitis 10.2
30 syncope 10.2
31 pik3ca-related overgrowth syndrome 10.2
32 urethral stricture 10.2
33 alopecia, androgenetic, 1 10.2
34 proteasome-associated autoinflammatory syndrome 1 10.2
35 varicocele 10.2
36 chronic kidney disease 10.2
37 body mass index quantitative trait locus 11 10.1
38 non-alcoholic fatty liver disease 10.1
39 dyspepsia 10.1
40 liver disease 10.1
41 liver cirrhosis 10.1
42 diabetes mellitus 10.1
43 fatty liver disease 10.1
44 cytokine deficiency 10.1
45 inguinal hernia 10.1
46 prostate disease 10.1
47 diabetes mellitus, noninsulin-dependent 10.1
48 body mass index quantitative trait locus 9 10.1
49 body mass index quantitative trait locus 8 10.1
50 body mass index quantitative trait locus 4 10.1

Graphical network of the top 20 diseases related to Prostatic Adenoma:



Diseases related to Prostatic Adenoma

Symptoms & Phenotypes for Prostatic Adenoma

UMLS symptoms related to Prostatic Adenoma:


prostatism

GenomeRNAi Phenotypes related to Prostatic Adenoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 8.8 ADRA1A ADRA1D ADRA2B

MGI Mouse Phenotypes related to Prostatic Adenoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.1 ADRA1A ADRA1D ADRA2A ADRA2B ADRA2C ADRB1

Drugs & Therapeutics for Prostatic Adenoma

Drugs for Prostatic Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 213)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Scopolamine Approved, Investigational Phase 4 6533-68-2, 51-34-3 5184
2
Saw palmetto Approved, Experimental, Investigational Phase 4
3
Silodosin Approved Phase 4 160970-54-7
4
Finasteride Approved Phase 4 98319-26-7 57363
5
Sodium citrate Approved, Investigational Phase 4 68-04-2
6
carbamide peroxide Approved Phase 4 124-43-6
7
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
8
Methyltestosterone Approved Phase 4 58-18-4 6010
9
Testosterone enanthate Approved Phase 4 315-37-7 9416
10
Testosterone Approved, Experimental, Investigational Phase 4 481-30-1, 58-22-0 6013 10204
11
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
12
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
13
Tranexamic Acid Approved Phase 4 1197-18-8 5526
14
Dihydrotachysterol Approved Phase 4 67-96-9 5311071 5281010
15
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
16
Fesoterodine Approved Phase 4 286930-03-8, 286930-02-7 6918558
17
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 5195 26757
18
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
19
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
20
Mirabegron Approved Phase 4 223673-61-8 9865528
21
Methoxyflurane Approved, Investigational, Vet_approved Phase 4 76-38-0 4116
22
Dutasteride Approved, Investigational Phase 4 164656-23-9 152945 6918296
23
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
24
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
25
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
26
Cimetropium Experimental, Investigational Phase 4 150521-16-7
27 Naftopidil Investigational Phase 4 57149-07-2
28
Dihydrotestosterone Illicit, Investigational Phase 4 521-18-6 10635
29
Fibrinolysin Investigational Phase 4 9004-09-5
30 Cola Phase 4
31 Anticonvulsants Phase 4
32 Bromides Phase 4
33 Autonomic Agents Phase 4
34 Antiemetics Phase 4
35 Gastrointestinal Agents Phase 4
36 Mydriatics Phase 4
37 Butylscopolammonium Bromide Phase 4
38 Anti-Infective Agents Phase 4
39 Saw palmetto extract Phase 4
40 Cholinergic Agents Phase 4
41 Platelet Aggregation Inhibitors Phase 4
42 calcium channel blockers Phase 4
43 Calcium, Dietary Phase 4
44 Muscarinic Antagonists Phase 4
45 Solifenacin succinate Phase 4 242478-38-2
46 Cholinergic Antagonists Phase 4
47 Sildenafil Citrate Phase 4 171599-83-0
48 Citrate Phase 4
49 Mitogens Phase 4
50 Endothelial Growth Factors Phase 4

Interventional clinical trials:

(show top 50) (show all 526)
# Name Status NCT ID Phase Drugs
1 Clinical Pilot Trial on the Influence of a Saw Palmetto Berry Preparation on Sexual Functions in Patients With Benign Prostatic Hyperplasia Unknown status NCT01021267 Phase 4 Saw palmetto berry extract
2 Comparison Between Alpha Blocker Monotherapy and 5-alpha-reductase Inhibitor Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia Unknown status NCT01301599 Phase 4 combination therapy;alpha blocker monotherapy;5 alpha reductase inhibitor monotherapy
3 Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia Unknown status NCT02034604 Phase 4 Naftofidil;Tamsulosin
4 A Prospective Multicenter Randomized Study Comparing Photoselective Vaporization of the Prostate With the GreenLight XPS™ Laser System and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Hyperplasia (The Goliath Study) Unknown status NCT01218672 Phase 4
5 Switch Study: Are There Any Measurable Differences When Switching Patients on Finasteride Therapy to Dutasteride? Unknown status NCT00690950 Phase 4 Dutasteride
6 Kinetics of the Finasteride Prostate Induced Apoptosis Unknown status NCT00130767 Phase 4 finasteride
7 Usefulness Of Flospan As A Premedication For Colonoscopy : A Randomized Double Blind Controlled Trial Unknown status NCT01842932 Phase 4 Phloroglucin;Cimetropium bromide;Placebo
8 Post-Marketing Study Using PROLIEVE® for the Treatment of Benign Prostatic Hyperplasia (BPH) Unknown status NCT02021032 Phase 4
9 Prospective Non-randomized Trial Comparing Holmium Laser Enucleation of the Prostate Versus Greenlight Laser Photoselective Vaporization of the Prostate in Treating Benign Prostate Hyperplasia in Patients With Bleeding Tendency Unknown status NCT02293759 Phase 4
10 Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)for the Treatment of Clinically Significant Benign Prostate Hyperplasia (BPH) Unknown status NCT00826527 Phase 4 Solifenacin PO
11 Does Hyoscine N-butylbromide Administered During Colonoscopy Increase the Polyp Detection Rate? a Randomized, Single Center, Double Blind, Placebo-controlled Study Unknown status NCT01609855 Phase 4 Hyoscine Butyl Bromide 20mg/2 ml i.v.;Saline 2 ml i.v.
12 Prostatic Artery Embolization Versus 532 nm Green Light Laser Photoselective Vaporization of the Prostate for Treating Catheter-Dependent Patients With Benign Prostatic Hyperplasia: A Randomized Controlled Clinical Study Unknown status NCT02006303 Phase 4
13 Behavior and Exercise Versus Drug Treatment in Men With Nocturia Unknown status NCT00824200 Phase 4 tamsulosin (alpha-adrenergic antagonist medication);placebo
14 Comparation the Effect of C-LMA and I-gel in Regurgitation and Postoperative Complications Unknown status NCT01876836 Phase 4
15 A Multicenter, Randomized, Double-blind, Clinical Study to Investigate the Efficacy and Safety of Treatment With Tamsulosin 0.2mg Mono and Tamsulosin 0.2mg, Finasteride 5mg Combination Therapy in Patients With LUTS/BPH Unknown status NCT01736033 Phase 4 Tamsulosin;Finasteride;Placebo
16 Low Dose, Low Concentration Different Baricity Bupivacaine for Transuretral Prostatectomy. Unknown status NCT01861041 Phase 4 Heavy Bupivacaine;Isobaric Bupivacaine
17 Comparison of the Efficacy and Safety of Combination Treatment With Doxazosin Plus TolterodineSR 2 mg vs Doxazosin Plus TolterodineSR 4 mg in Men With an OAB/BPO: Randomized Controlled Study" Unknown status NCT00922506 Phase 4 doxazosin plus tolterodine SR
18 Ejaculatory Sparing vs. Non-ejaculatory Sparing GreenLightTM Laser Photoselective Vaporization of the Prostate (PVP): A Randomized Double Blind Sexual and Urodynamic Assessment Unknown status NCT02749604 Phase 4
19 The Effect of KTP (Potassium-titanyl-phosphate) Green Light Prostatectomy (180W) Compared With Open Prostatectomy When Treating Benign Prostatic Hyperplasia, a Prospective Randomized Study Completed NCT02072499 Phase 4
20 A 12-week, Open Label, Multi-center Study to Investigate the Efficacy and Safety of a α1A Adrenoceptor Selective Antagonist Silodosin on Urinary Disturbance Associated With Benign Prostatic Hyperplasia Completed NCT01259531 Phase 4 Silodosin
21 PERMIXON® 160 mg Hard Capsule Versus Placebo in the Treatment of Symptomatic Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia Completed NCT02121613 Phase 4 Permixon® 160 mg;Tamsulosine LP;Placebo matching Permixon® 160 mg;Placebo matching Tamsulosine LP
22 An Open-Label Randomized Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia Completed NCT01500057 Phase 4
23 A Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Tamsulosin OCAS 0.4 mg Tablets, Once Daily on Nocturia, Compared to Placebo, in Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia Completed NCT00379067 Phase 4 Tamsulosin OCAS;Placebo
24 Evaluation of the Effect of 10 mg Alfuzosin (Alfetim Uno®) o. d. in Patients Presenting Low-Urinary Tract Symptoms Completed NCT00637715 Phase 4 Alfuzosin
25 Study of the Outcome of Patients With Lower Urinary Symptoms Suggestive of Benign Prostatic Hyperplasia and Treated With Alfuzosin 10 mg Once Daily for 3 Months in China Completed NCT00280605 Phase 4 Alfuzosin
26 A Forty-Five Day, Open-label Study of the Symptomatic Relief Effects of FLOMAX® Capsules 0.4 mg Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244242 Phase 4 Tamsulosin hydrochloride
27 An Eleven-Week, Open-Label, Randomized, Multicenter, Parallel-Design, Placebo Lead-in Study of FLOMAX® Capsules, 0.4 mg Daily Versus HYTRIN® Capsules, 5 mg (With Titration) Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244255 Phase 4 FLOMAX® capsules;Ascending doses of HYTRIN® capsules
28 A Post-Marketing Clinical Study of LY450190 (Combined With Alpha1 Blocker Treatment) Completed NCT02431754 Phase 4 Tadalafil;Placebo;Alpha1 Blocker
29 A Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Design Clinical Trial to Evaluate the Efficacy and Safety of Naftopidil in Male Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia Completed NCT01922375 Phase 4 Naftopidil
30 Evaluation of the Effects of Monopolar Transurethral Resection Versus Bipolar Transurethral Resection and Holmium Laser Enucleation of the Prostate on Urinary and Sexual Function; a Prospective Comparative Study. Completed NCT01810068 Phase 4
31 Green Light Laser (XPS) Photoselective Vaporization of the Prostate (PVP) Versus Bipolar Transurethral Vaporization (B.TUVP) of the Prostate for Treatment of Small to Moderate Sized Benign Prostate Hyperplasia: A Randomized Study Completed NCT02283684 Phase 4
32 Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin 10mg Once Daily (XATRAL 10mg OD), Open, 24-week Study. Completed NCT00401661 Phase 4 Alfuzosin
33 Apoptosis and Expression of Neovascularization-related Factors in Human Prostate Tissue After Administration of Dutasteride Completed NCT00880672 Phase 4 dutasteride
34 BLADDER (BPH, LUTS And Detrusor: Dual Effect Research) Study: A Multicentre, Double-blind, Randomised, Parallel Group, Placebo-controlled Study, Aimed at Characterising the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms Completed NCT02245490 Phase 4 Tamsulosin HCl controlled release capsules;Matching placebo capsule
35 Effectiveness and Safety of Silodosin in the Treatment of LUTS in Patients With Benign Prostatic Hyperplasia: a European Phase IV Clinical Study. The Silodosin in Real-life Evaluation Study Completed NCT01757769 Phase 4 Silodosin
36 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of Solifenacin Succinate as Add-on Therapy for Overactive Bladder (OAB) Symptoms in Men Treated for Benign Prostatic Hyperplasia (BPH) With Tamsulosin Hydrochloride Completed NCT00771394 Phase 4 Tamsulosin hydrochloride;Solifenacin succinate
37 An Open-label, Prospective Interventional Study of the Tolerability and Efficacy of Oral Harnalidge® OCAS® (Tamsulosin) 0.4 mg in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2 mg Completed NCT02180789 Phase 4 Tamsulosin OCAS
38 A Multi-center, Prospective, Open-label, Single-arm, 12-weeks, Phase IV Trial to Evaluate the Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia Completed NCT02106182 Phase 4 Silodosin
39 A Randomized, Open-label, Parallel-group Study, to Assess the Pharmocodynamic Effect on Dihydrotestosterone Regulated Gene Expression, Longitudinally and in a Dose Dependent Manner, of 0.5mg and 3.5mg Dutasteride Administered Orally Once Daily, for One Year in Men With Symptomatic Benign Prostatic Hyperplasia and During a Two Month Period Between Baseline and Radical Prostatectomy in Men With Biopsy-proven, Clinically Localized Prostate Cancer Completed NCT00375765 Phase 4 Dutasteride
40 ALEX-XL: Alfuzosin XL-Lower Urinary Tract Symptoms Efficacy and Sexuality Study Completed NCT00575913 Phase 4 Alfuzosin
41 A Prospective Clinical Study for GreenLight HPS in the Treatment of Obstructive Benign Prostatic Hyperplasia (BPH) Completed NCT00465101 Phase 4
42 A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo-Controlled Flexible Dose Study With and Open-Label Extension to Assess the Efficacy and Safety of Viagra (Sildenafil Citrate) in the Treatment of Men With Erectile Dysfunction (ED) and Concomitant Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) in the United States Completed NCT00143221 Phase 4 Viagra;Placebo
43 A Phase 4, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Mirabegron in Japanese and Korean Male Patients With Overactive Bladder Under Treatment With the α-Blocker Tamsulosin for Benign Prostatic Hyperplasia Completed NCT02656173 Phase 4 Mirabegron;Placebo;Tamsulosin
44 A Prospective Evaluation of the GreenLight Model 120 Laser System for the Treatment of Benign Prostatic Hyperplasia Completed NCT00364585 Phase 4
45 Dutasteride (0.5mg) Once Daily for One Year and Tamsulosin (0.4mg) Once Daily for 3 Months, Followed by Counseling on Flex Dose Tamsulosin as Needed on Improvement of Symptoms and Outcome in Men With Moderate to Severe Symptomatic BPH Completed NCT00701779 Phase 4 Tamsulosin
46 Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin 10mg Once Daily (XATRAL OD 10mg), Open, 24-week Study Completed NCT00486785 Phase 4 Alfuzosin
47 MICTUS (Multicentre Investigation to Characterise the Effect of Tamsulosin on Urinary Symptoms): A Multicentre, Double-blind, Randomised, Parallel Group Study, Aimed at Characterising the Effect of Tamsulosin, an Uroselective α1- Receptor Blocking Agent, on the Urological Symptoms and Their Impact on General Health Status and Quality of Life in Outpatients Affected by Symptomatic Benign Prostatic Hyperplasia: Comparison With Finasteride. Completed NCT02244229 Phase 4 Tamsulosin;Finasteride;Placebo
48 Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration Completed NCT02041767 Phase 4 Ertapenem
49 The Long Term Effects of Alfuzosin (Xatral XL) in LUTS/BPH Patients: Evaluation of Symptom-specific Goal Achievement According to Symptom Improvement, Bladder Outlet Obstruction Grade and Bladder Contractility Completed NCT00836823 Phase 4 Alfuzosin
50 A Prospective Randomized Clinical Trial of Bipolar vs Monopolar Transurethral Resection of the Prostate (TURP) Completed NCT00199550 Phase 4

Search NIH Clinical Center for Prostatic Adenoma

Inferred drug relations via UMLS 72 / NDF-RT 51 :


alfuzosin
Doxazosin
Doxazosin Mesylate
Dutasteride
Finasteride
Leuprolide
Leuprolide Acetate
Prazosin
Prazosin hydrochloride
Saw palmetto extract
silodosin
tamsulosin
Tamsulosin hydrochloride
Terazosin
terazosin hydrochloride

Cochrane evidence based reviews: prostatic hyperplasia

Genetic Tests for Prostatic Adenoma

Anatomical Context for Prostatic Adenoma

MalaCards organs/tissues related to Prostatic Adenoma:

41
Prostate, Testes, Smooth Muscle, Bone, Endothelial, Kidney, Liver

The Foundational Model of Anatomy Ontology organs/tissues related to Prostatic Adenoma:

19
Prostate

Publications for Prostatic Adenoma

Articles related to Prostatic Adenoma:

(show top 50) (show all 14259)
# Title Authors PMID Year
1
[Efficacy and safety of combined treatment of prostatic adenoma with 5-alpha reductase and alpha-adrenoblockers]. 9 38
20169718 2009
2
[The experience in dutasteride use before transurethral prostatic resection for large adenoma]. 9 38
19054996 2008
3
[Dutasteride--an inhibitor of 5alpha-reductase of type I and II--in the treatment of patients with prostatic adenoma. What is the latest news?]. 9 38
18652016 2007
4
[Treatment of prostatic adenoma patients with inhibitor of 5-alpha-reductase of type I and II avodart (dutasteride)]. 9 38
17315721 2006
5
Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years. 9 38
16686717 2006
6
[Proscar (finasteride, MSD) in the treatment of patients with prostatic hyperplasia]. 9 38
8928344 1996
7
Effect of digital rectal examination on plasma prostate-specific antigen (PSA). 9 38
8836791 1996
8
The efficacy of finasteride in the treatment of symptomatic benign prostatic hyperplasia. 9 38
8851481 1995
9
Relationship between prostate-specific antigen, prostate volume, retention volume and age in benign prostatic hypertrophy (BPH). 9 38
8725044 1995
10
Predicted and actual change in serum PSA following prostatectomy for BPH. 9 38
7512298 1994
11
[Effect of rectal examination in patients with prostatic adenoma on concentration of prostatic specific antigen (PSA) in plasma]. 9 38
7526558 1993
12
Experience with prostate-specific antigen in prostatic carcinoma. 9 38
1718923 1991
13
[5-alpha reductase inhibitor in prostatic adenoma?]. 9 38
1705307 1990
14
Effects of Lespedeza Cuneata aqueous extract on testosterone-induced prostatic hyperplasia. 38
30724641 2019
15
Identification of key genes and pathways in benign prostatic hyperplasia. 38
31187492 2019
16
Minimally Invasive Radical Prostatectomy after Previous Bladder Outlet Surgery: A Systematic Review and Pooled Analysis of Comparative Studies. 38
31039100 2019
17
Transition zone prostate cancer: Logistic regression and machine-learning models of quantitative ADC, shape and texture features are highly accurate for diagnosis. 38
30701625 2019
18
Re: Second-Generation of Temporary Implantable Nitinol Device for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Results of a Prospective, Multicentre Study at 1 Year of Follow-up. 38
31219387 2019
19
Re: Extreme Price Variation for Generic Benign Prostatic Hyperplasia Medications. 38
31219374 2019
20
Outcome after prostatic artery embolization in patients with symptomatic benign prostatic hyperplasia. 38
30450921 2019
21
Oxidative stress before and after surgery in benign prostatic hyperplasia patients. 38
31158928 2019
22
It's Time to Take Advantage of Robotic Assisted Simple Prostatectomy in Large Benign Prostatic Hyperplasia. 38
30588785 2019
23
The Relationships between Thyroid Hormone Levels and Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia. 38
30644234 2019
24
NICE Guidance - Transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. 38
31436038 2019
25
Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Amendment 2019. 38
31059668 2019
26
Homology Modeling of 5-alpha-Reductase 2 Using Available Experimental Data. 38
29383563 2019
27
Evaluation of neurotensin receptor 1 as potential biomarker for prostate cancer theranostic use. 38
31264168 2019
28
Suppressor of activator protein-1 regulated by interferon expression in prostate cancer tissues and cells. 38
31276688 2019
29
Multimodality approach to imaging giant multilocular cystadenoma of the prostate: A rare entity. 38
31338138 2019
30
Characterization and screening of cyclooxygenase-2 inhibitors from Zi-shen pill by affinity ultrafiltration-ultra performance liquid chromatography mass spectrometry. 38
31029761 2019
31
Oxidised low-density lipoprotein, a possible distinguishing lipid profile biomolecule between prostate cancer and benign prostatic hyperplasia. 38
31145504 2019
32
Effects of dexamethasone on postoperative urinary retention after laparoscopic inguinal hernia repair. 38
30406386 2019
33
Increased Expression of miR-494 in Serum of Patients with Prostate Cancer and its Potential Diagnostic Value. 38
31414754 2019
34
Epidemiology Update of Erectile Dysfunction in Eight Countries with High Burden. 38
31416758 2019
35
A NAV2729-sensitive mechanism promotes adrenergic smooth muscle contraction and growth of stromal cells in the human prostate. 38
31243101 2019
36
Changes in the oxidative stress factors and inflammatory proteins following the treatment of BPH-induced dogs with an anti-proliferative agent called tadalafil. 38
31410874 2019
37
Comparison of Diode Laser (980 nm) Enucleation vs Holmium Laser Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia: A Randomized Controlled Trial with 12-Month Follow-Up. 38
31298571 2019
38
Medical treatment for benign prostatic hyperplasia: Where do we stand? 38
31282310 2019
39
Quantitation of Lipid Peroxidation Product DNA Adducts in Human Prostate by Tandem Mass Spectrometry: A Method That Mitigates Artifacts. 38
31361128 2019
40
Expansion of Luminal Progenitor Cells in the Aging Mouse and Human Prostate. 38
31390564 2019
41
Testosterone therapy: a friend or a foe for the aging men with benign prostatic hyperplasia? 38
31424029 2019
42
Regulation of PDE5 expression in normal prostate, benign prostatic hyperplasia, and adenocarcinoma. 38
31433119 2019
43
The Utilization of Benign Prostatic Hyperplasia and Bladder-Related Medications After a Transurethral Prostatectomy. 38
31129193 2019
44
Re: Association of Prostatic Volume and Carotid Intima-Media Thickness in Patients with Benign Prostatic Hyperplasia. 38
31021287 2019
45
Re: Convective Radiofrequency Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia: A Single Office Experience. 38
31021289 2019
46
Re: Allopurinol and Risk of Benign Prostatic Hyperplasia in a Finnish Population-Based Cohort. 38
31021294 2019
47
6-Sialyllactose Ameliorates Dihydrotestosterone-induced Benign Prostatic Hyperplasia through Suppressing VEGF-mediated Angiogenesis. 38
31383249 2019
48
Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms: What Is the Role and Significance of Inflammation? 38
31377881 2019
49
Incontinence after Prostate Treatment: AUA/SUFU Guideline. 38
31059663 2019
50
Current Knowledge of the Potential Links between Inflammation and Prostate Cancer. 38
31390729 2019

Variations for Prostatic Adenoma

Expression for Prostatic Adenoma

Search GEO for disease gene expression data for Prostatic Adenoma.

Pathways for Prostatic Adenoma

Pathways related to Prostatic Adenoma according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.76 KLK3 ADRB1 ADRA2C ADRA2B ADRA2A ADRA1D
2
Show member pathways
13.19 ADRB1 ADRA2C ADRA2B ADRA2A ADRA1D ADRA1A
3
Show member pathways
13.05 NUDT6 ADRB1 ADRA2C ADRA2B ADRA2A ADRA1D
4
Show member pathways
12.52 ADRB1 ADRA1D ADRA1A
5
Show member pathways
12.52 ADRB1 ADRA2B ADRA2A ADRA1A
6
Show member pathways
12.26 ADRA2C ADRA2B ADRA2A
7
Show member pathways
12.23 ADRA2C ADRA2B ADRA2A
8
Show member pathways
12.21 ADRB1 ADRA1D ADRA1A
9
Show member pathways
11.97 ADRB1 ADRA1D ADRA1A
10
Show member pathways
11.85 ADRB1 ADRA1D ADRA1A
11
Show member pathways
11.79 ADRA2C ADRA2B ADRA2A ADRA1D ADRA1A
12
Show member pathways
11.57 ADRA2C ADRA2B ADRA2A
13
Show member pathways
11.47 ADRB1 ADRA2C ADRA2B ADRA2A ADRA1D ADRA1A
14 11.25 ADRB1 ADRA2A ADRA1D
15
Show member pathways
11.17 ADRA2C ADRA2A
16 11.05 ADRB1 ADRA2B ADRA2A ADRA1A
17 11.04 ADRB1 ADRA1A
18 10.46 ADRB1 ADRA2C ADRA2B ADRA2A ADRA1D ADRA1A

GO Terms for Prostatic Adenoma

Cellular components related to Prostatic Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.1 ADRB1 ADRA2C ADRA2B ADRA2A ADRA1D ADRA1A
2 integral component of postsynaptic membrane GO:0099055 8.96 ADRA2C ADRA1A
3 integral component of postsynaptic density membrane GO:0099061 8.85 ADRA2C

Biological processes related to Prostatic Adenoma according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.84 ADRA2C ADRA2B ADRA1D ADRA1A
2 positive regulation of MAPK cascade GO:0043410 9.76 ADRA2C ADRA2B ADRA2A ADRA1A
3 platelet activation GO:0030168 9.73 ADRA2C ADRA2B ADRA2A
4 activation of protein kinase B activity GO:0032148 9.65 ADRA2C ADRA2B ADRA2A
5 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.63 ADRB1 ADRA2C ADRA2B ADRA2A ADRA1D ADRA1A
6 regulation of smooth muscle contraction GO:0006940 9.61 ADRA2C ADRA2B ADRA2A
7 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.6 ADRB1 ADRA2A
8 female pregnancy GO:0007565 9.59 ADRA2C ADRA2B
9 positive regulation of neuron differentiation GO:0045666 9.58 ADRA2C ADRA2B
10 regulation of insulin secretion GO:0050796 9.58 ADRA2C ADRA2A
11 negative regulation of norepinephrine secretion GO:0010700 9.58 ADRA2C ADRA2B ADRA2A
12 positive regulation of vasoconstriction GO:0045907 9.57 ADRA2C ADRA1A
13 regulation of vasoconstriction GO:0019229 9.56 ADRA2C ADRA2B ADRA2A ADRA1A
14 receptor transactivation GO:0035624 9.54 ADRA2C ADRA2B ADRA2A
15 positive regulation of the force of heart contraction by epinephrine-norepinephrine GO:0001997 9.51 ADRB1 ADRA1A
16 negative regulation of epinephrine secretion GO:0032811 9.5 ADRA2C ADRA2B ADRA2A
17 positive regulation of heart rate by epinephrine-norepinephrine GO:0001996 9.49 ADRB1 ADRA1A
18 adrenergic receptor signaling pathway GO:0071875 9.35 ADRA2C ADRA2B ADRA2A ADRA1D ADRA1A
19 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.1 ADRB1 ADRA2C ADRA2B ADRA2A ADRA1D ADRA1A
20 signal transduction GO:0007165 10.02 ADRB1 ADRA2C ADRA2B ADRA2A ADRA1D ADRA1A
21 G protein-coupled receptor signaling pathway GO:0007186 10 ADRB1 ADRA2C ADRA2B ADRA2A ADRA1D ADRA1A

Molecular functions related to Prostatic Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.73 ADRB1 ADRA2B ADRA2A ADRA1A
2 protein heterodimerization activity GO:0046982 9.71 ADRB1 ADRA2C ADRA2A ADRA1A
3 norepinephrine binding GO:0051380 9.37 ADRB1 ADRA2A
4 alpha2-adrenergic receptor activity GO:0004938 9.33 ADRA2C ADRA2B ADRA2A
5 alpha-2A adrenergic receptor binding GO:0031694 9.32 ADRB1 ADRA2C
6 alpha1-adrenergic receptor activity GO:0004937 9.26 ADRA1D ADRA1A
7 epinephrine binding GO:0051379 9.26 ADRB1 ADRA2C ADRA2B ADRA2A
8 adrenergic receptor activity GO:0004935 9.1 ADRB1 ADRA2C ADRA2B ADRA2A ADRA1D ADRA1A

Sources for Prostatic Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....